1. Pink Sheet
  3. >>Asia
  4. >>South Korea

New Korea Commission Needs Status To Function As Control Tower: Industry

KPBMA Says Broad Policy Direction Still Ambiguous

 
• By Jung Won Shin

A policy report by a major South Korean pharma industry association puts forward suggestions on what it will take for a new pan-government control tower to function properly.

new attempt
Similar Attempts In The Past, But Governance Issues Continue To Be Raised • Source: Shutterstock

South Korea’s Biohealth Innovation Commission, a pan-government entity tasked to act as a "control tower," is set to officially launch soon in an attempt to to more comprehensively and systematically coordinate currently fragmented policies and strategies in the sector.

But setting up a new commission is unlikely itself to complete the governance system to enable the country's biopharma industry...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Asia

To Compete With China, US FDA Must Deregulate Early Gene Therapy Studies, CAR-T Inventor Says

 
• By Sarah Karlin-Smith

FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.

New Era Begins In Korea: Policy Predictions For Biopharma

 
• By Jung Won Shin

As South Korea's new president immediately gets to work on setting initial policies, essential drug supplies, R&D incentives and AI-driven digital healthcare are among the key topics in focus.

Australia Looks To Modernize Human Tissue Laws, Improving Access For Researchers

 
• By Eliza Slawther

Australia is reviewing its human tissue laws for the first time in almost 50 years, and is hoping to reduce barriers to access for scientific researchers, for instance by addressing issues with access to cell lines for developing drugs.